- Home
- QSI vs FENC Comparison
QSI vs FENC Comparison
Compare QSI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QSI | FENC |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.7M | 258.5M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | QSI | FENC |
|---|---|---|
| Price | $1.26 | $7.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.88 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 4.2M | 156.3K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,177,000.00 | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $159.68 | $75.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 40.20 | N/A |
| 52 Week Low | $0.95 | $4.68 |
| 52 Week High | $5.77 | $9.92 |
Technical Indicators
Market Signals| Indicator | QSI | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 45.04 |
| Support Level | $1.18 | $7.50 |
| Resistance Level | $1.31 | $8.00 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 20.83 | 36.92 |
Price Performance
Historical ComparisonAbout QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.